Tesaro Inc. (NASDAQ:TSRO) had its target price upped by analysts at FBR & Co from $102.00 to $115.00 in a research report issued to clients and investors on Monday. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. FBR & Co’s price target points to a potential upside of 15.86% from the stock’s previous close.

A number of other equities analysts have also weighed in on the stock. SunTrust Banks Inc. reissued a “buy” rating and issued a $91.60 price objective on shares of Tesaro in a research report on Wednesday, September 14th. Lake Street Capital reissued a “buy” rating and issued a $114.00 price objective on shares of Tesaro in a research report on Tuesday, September 6th. Bank of America Corp. assumed coverage on shares of Tesaro in a report on Tuesday, August 30th. They issued a “neutral” rating and a $97.00 target price for the company. Leerink Swann restated an “outperform” rating and issued a $108.00 target price on shares of Tesaro in a report on Thursday, August 25th. Finally, RBC Capital Markets restated an “outperform” rating and issued a $122.00 target price on shares of Tesaro in a report on Wednesday, August 24th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $95.97.

Analyst Recommendations for Tesaro (NASDAQ:TSRO)

Tesaro (NASDAQ:TSRO) opened at 99.26 on Monday. The company’s 50 day moving average is $96.42 and its 200 day moving average is $68.96. The firm’s market cap is $5.10 billion. Tesaro has a 52-week low of $29.51 and a 52-week high of $110.48.

Tesaro (NASDAQ:TSRO) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.43. The company earned $36.60 million during the quarter, compared to analysts’ expectations of $4.98 million. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. During the same quarter in the previous year, the business posted ($1.51) earnings per share. Equities research analysts forecast that Tesaro will post ($7.36) EPS for the current fiscal year.

In other Tesaro news, VP Edward C. English sold 7,000 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $88.54, for a total value of $619,780.00. Following the completion of the transaction, the vice president now directly owns 3,500 shares of the company’s stock, valued at approximately $309,890. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Jeffrey H. Hanke sold 29,166 shares of the company’s stock in a transaction dated Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the completion of the transaction, the vice president now directly owns 29,166 shares of the company’s stock, valued at $2,509,442.64. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of TSRO. KCG Holdings Inc. purchased a new position in Tesaro during the second quarter worth $228,000. Quantitative Systematic Strategies LLC purchased a new position in Tesaro during the second quarter worth $240,000. Bluestein R H & Co. purchased a new position in Tesaro during the second quarter worth $252,000. Neuberger Berman Group LLC purchased a new position in Tesaro during the second quarter worth $256,000. Finally, Amalgamated Bank bought a new stake in shares of Tesaro during the second quarter worth about $260,000. 88.81% of the stock is owned by institutional investors.

About Tesaro

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Stock Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related stocks with our FREE daily email newsletter.